SCHEMBL10033006

SCHEMBL10033006

COc1ccc(NC(C)=O)cc1C(=O)NO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.63
MAPK1 P28482 1/20 0.57
HDAC8 Q9BY41 5/20 0.57
HDAC1 Q13547 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
MAPT P10636 5/20 0.52
POLB P06746 2/20 0.52
GFER P55789 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
PDE5A O76074 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HTT P42858 2/20 0.50
KDM4E B2RXH2 1/20 0.50
STAT3 P40763 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
CDK1 P06493 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721054 0.88 MAPK1 (0.57) ALDH1A1MAPK1HDAC8MAPTPOLB
SCHEMBL130408 0.85 ALDH1A1 (0.64) ALDH1A1MAPK1MAPTPOLBSMN1; SMN2
SCHEMBL7000380 0.84 ALDH1A1 (0.59) ALDH1A1MAPK1MAPTPOLBSMN1; SMN2
SCHEMBL7000701 0.84 SMN1; SMN2 (0.64) ALDH1A1MAPK1MAPTPOLBSMN1; SMN2
SCHEMBL10033014 0.84 RORC (0.63) ALDH1A1MAPK1HDAC8HDAC1HDAC6
SCHEMBL10033005 0.84 TDP1 (0.63) ALDH1A1HDAC8HDAC1HDAC6MAPT
SCHEMBL12505394 0.83 ALDH1A1 (0.57) ALDH1A1MAPK1MAPTPOLBSMN1; SMN2
SCHEMBL30492996 0.80 SMN1; SMN2 (0.68) ALDH1A1MAPK1MAPTPOLBSMN1; SMN2
SCHEMBL1851780 0.80 SMN1; SMN2 (0.68) ALDH1A1MAPK1MAPTPOLBSMN1; SMN2
SCHEMBL30355120 0.79 LMNA (0.66) ALDH1A1MAPK1MAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753365-B2 Methods of treating fibrosis NOGRA PHARMA LIMITED (IE) 2023-09-12 US disclosed
US-11753365-B2 Methods of treating fibrosis NOGRA PHARMA LIMITED (IE) 2023-09-12 US disclosed
US-20220354809-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2022-11-10 US disclosed
US-20220033346-A1 METHODS OF TREATING FIBROSIS NOGRA PHARMA LIMITED (IE) 2022-02-03 US disclosed
US-20210113505-A1 METHODS OF TREATING HAIR RELATED CONDITIONS NOGRA PHARMA LTD (IE) 2021-04-22 US disclosed
US-10959970-B2 Methods of treating hair related conditions NOGRA PHARMA LIMITED (IE) 2021-03-30 US disclosed
US-20200383942-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2020-12-10 US disclosed
US-20200188340-A1 Methods of Treating Hair Related Conditions GIULIANI INTERNATIONAL, LTD. (IE) 2020-06-18 US disclosed
US-20190269637-A1 Alkylamido Compounds and Uses Thereof GIULIANI INTERNATIONAL, LTD. (IE) 2019-09-05 US disclosed
US-10398667-B2 Methods of treating hair related conditions NOGRA PHARMA LIMITED (IE) 2019-09-03 US disclosed
US-20150087678-A1 METHODS OF TREATING LACTOSE INTOLERANCE NOGRA PHARMA LIMITED (IE) 2015-03-26 US disclosed
US-20150087678-A1 METHODS OF TREATING LACTOSE INTOLERANCE NOGRA PHARMA LIMITED (IE) 2015-03-26 US disclosed
US-20150051285-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2015-02-19 US disclosed
US-20150051285-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2015-02-19 US disclosed
US-8796334-B2 Methods of treating hair related conditions NOGRA PHARMA LIMITED (IE) 2014-08-05 US disclosed
US-8796334-B2 Methods of treating hair related conditions NOGRA PHARMA LIMITED (IE) 2014-08-05 US disclosed
US-8754127-B2 Alkylamido compounds and uses thereof NOGRA PHARMA LIMITED (IE) 2014-06-17 US disclosed
US-8754127-B2 Alkylamido compounds and uses thereof NOGRA PHARMA LIMITED (IE) 2014-06-17 US disclosed
US-20120053245-A1 Methods of Treating Hair Related Conditions GIULIANI INTERNATIONAL, LTD. (IE) 2012-03-01 US disclosed
US-20120053244-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220354809-A1 Alkylamido Compounds and Uses Thereof EGFR, PPARG, ERBB3 ALDH1A1 2715/4885MAPK1 1192/4885HDAC8 697/4885
US-20190269637-A1 Alkylamido Compounds and Uses Thereof EGFR, PPARG, ERBB3 ALDH1A1 2715/4885MAPK1 1192/4885HDAC8 697/4885
US-20200383942-A1 Alkylamido Compounds and Uses Thereof EGFR, PPARG, ERBB3 ALDH1A1 2715/4885MAPK1 1192/4885HDAC8 697/4885
US-20150051285-A1 Alkylamido Compounds and Uses Thereof EGFR, PPARG, ERBB3 ALDH1A1 2715/4885MAPK1 1192/4885HDAC8 697/4885
US-11753365-B2 Methods of treating fibrosis MMP1, MMP8, FABP2 ALDH1A1 664/4885MAPK1 4456/4885HDAC8 815/4885
US-20120053245-A1 Methods of Treating Hair Related Conditions PPARA, PPARG, PPARD ALDH1A1 159/4885MAPK1 3982/4885HDAC8 161/4885
US-20210113505-A1 METHODS OF TREATING HAIR RELATED CONDITIONS EBP, AADAT, ALDH7A1 ALDH1A1 53/4885MAPK1 2730/4885HDAC8 472/4885
US-20150087678-A1 METHODS OF TREATING LACTOSE INTOLERANCE LCT, LPL, PPARG ALDH1A1 530/4885MAPK1 3839/4885HDAC8 521/4885
US-10398667-B2 Methods of treating hair related conditions PPARA, PPARG, PPARD ALDH1A1 159/4885MAPK1 3982/4885HDAC8 161/4885
US-10959970-B2 Methods of treating hair related conditions PPARA, PPARG, PPARD ALDH1A1 159/4885MAPK1 3982/4885HDAC8 161/4885
US-20200188340-A1 Methods of Treating Hair Related Conditions PPARA, PPARG, PPARD ALDH1A1 159/4885MAPK1 3982/4885HDAC8 161/4885
US-20120053244-A1 Alkylamido Compounds and Uses Thereof EGFR, PPARG, ERBB3 ALDH1A1 2715/4885MAPK1 1192/4885HDAC8 697/4885
US-20220033346-A1 METHODS OF TREATING FIBROSIS MMP1, MMP8, FABP2 ALDH1A1 664/4885MAPK1 4456/4885HDAC8 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.